Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$84.1 million.

  • Phathom Pharmaceuticals' Net Cash Flow fell 124.66% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.5 million, marking a year-over-year decrease of 264.89%. This contributed to the annual value of -$84.1 million for FY2024, which is 136.84% down from last year.
  • According to the latest figures from FY2024, Phathom Pharmaceuticals' Net Cash Flow is -$84.1 million, which was down 136.84% from $228.4 million recorded in FY2023.
  • Phathom Pharmaceuticals' Net Cash Flow's 5-year high stood at $228.4 million during FY2023, with a 5-year trough of -$104.1 million in FY2021.
  • For the 3-year period, Phathom Pharmaceuticals' Net Cash Flow averaged around $38.9 million, with its median value being -$27.5 million (2022).
  • In the last 5 years, Phathom Pharmaceuticals' Net Cash Flow slumped by 337.99% in 2021 and then surged by 929.55% in 2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Net Cash Flow (Yearly) stood at $43.7 million in 2020, then slumped by 337.99% to -$104.1 million in 2021, then spiked by 73.55% to -$27.5 million in 2022, then surged by 929.55% to $228.4 million in 2023, then tumbled by 136.84% to -$84.1 million in 2024.